Understand the source comparison
Best Peptides for Premature Ejaculation: Clinical Comparison
This table compares the peptides with actual PE-related clinical data. | Peptide | Primary Mechanism | Evidence Quality | Typical IELT Extension (Mean) | Onset Time | Known Limitations | Professional Assessment ||—|—|—|—|—|—|| Melanotan II | MC3R/MC4R agonist.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the peptides with actual PE-related clinical data.
- | Peptide | Primary Mechanism | Evidence Quality | Typical IELT Extension (Mean) | Onset Time | Known Limitations | Professional Assessment ||—|—|—|—|—|—|| Melanotan II | MC3R/MC4R agonist. Increases CNS dopamine and NO, modulates ejaculatory threshold | Moderate (Phase II human trials, N=40–60) | +1.8 minutes (40–60% from baseline in responders) | 4–6 hours post-injection | Nausea in 30–40%, skin darkening with chronic use, no FDA approval for PE | Strongest clinical evidence for acute latency extension; requires medical supervision || PT-141 (Bremelanotide) | Selective MC3R/MC4R agonist. Similar pathway to MT-II with improved selectivity | Low-Moderate (early-phase PE studies, FDA-approved for HSDD in women) | Variable (+0.5–2.0 minutes) | 45–60 minutes | Inconsistent responder rate, nausea, BP elevation | FDA-approved for desire but PE efficacy remains unproven; timing-sensitive || Oxytocin (intranasal) | Hypothalamic serotonin modulation via oxytocin receptors in brainstem nuclei |